Treatment of Fulminant Giant Cell Myocarditis Associated with Polymyositis Using a Left Ventricular Assist Device and Subsequent Corticosteroid and Immunosuppressive Therapy Leading to Remission
View Full Paper
Ask AI
Bookmark
Share
Key result
Left ventricular assist device implantation and subsequent corticosteroid and immunosuppressive therapy led to remission and recovery of left ventricular ejection fraction from 6% to 68%.
Why the study?
Does LVAD combined with corticosteroid and immunosuppressive therapy improve LVEF and clinical status in a patient with fulminant giant cell myocarditis associated with polymyositis?
Population
1 58-year-old man with fulminant giant cell myocarditis associated with polymyositis, presenting with…
Design
Case_report
Follow-up
2 months post-discharge
Authors
Discussion
Loading...
Member takes
Implication
May support recovery in fulminant giant cell myocarditis; hypothesis-generating and requires prospective validation before practice change.
Study Design
Type
Case Report (n=1)
Multicenter
No
Structured PICO
Does LVAD combined with corticosteroid and immunosuppressive therapy improve LVEF and clinical status in a patient with fulminant giant cell myocarditis associated with polymyositis?
P
Population
A 58-year-old man with fulminant giant cell myocarditis associated with polymyositis who presented with cardiogenic shock and was followed for 2 months after discharge.
I
Intervention
Left ventricular assist device (LVAD) implantation followed by intravenous methylprednisolone (1,000 mg daily for 3 days), maintenance prednisolone (50 mg daily), and cyclosporine (100 mg daily).
O
Outcome
Recovery of left ventricular ejection fraction (LVEF) and clinical remissionsurrogate
LVAD implantation followed by corticosteroid and immunosuppressive therapy can lead to successful recovery and remission in fulminant giant cell myocarditis associated with polymyositis.
Limitations
- Single case report
- The protocol of immune suppressive therapy in patients with giant cell myocarditis during the late-phase still remains controversial
Cite This Study
Ooka et al. (2017) conducted a case report in Fulminant giant cell myocarditis associated with polymyositis (n=1). Left ventricular assist device (LVAD) and subsequent corticosteroid and immunosuppressive therapy was evaluated on Left ventricular ejection fraction (LVEF) recovery. Left ventricular assist device implantation and subsequent corticosteroid and immunosuppressive therapy led to remission and recovery of left ventricular ejection fraction from 6% to 68%.
Topics
View Full Paper
Ask AI
Bookmark
Share